2022 Cannabinoids Clinical Trials Data 
Veriheal
JUNE 30, 2023
For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.
Cannabis Law Report
MAY 10, 2022
11 May 2022. First academic study of national medicinal cannabis data. The study, led by the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics , found anxiety was among the top three reasons for a medicinal cannabis prescription. The authors note, however, that the data doesn’t include patient outcomes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
JUNE 23, 2022
While CBG (cannabigerol) has been hailed ‘the mother of all cannabinoids,’ it’s time to reveal the true heir to the throne – cannabigerolic acid, or CBGA. This cannabinoid has only recently been studied, and future studies will certainly divulge its exact importance. Common cannabinoids in cannabis. What does CBGA do?
Cannabis Law Report
JANUARY 24, 2022
Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS
Cannabis Law Report
MAY 29, 2022
Clinical Trials and Human Subject Protections. Before the drug approval process even begins, sponsors must initiate clinical investigations by first filing an Investigational New Drug Application (IND) with FDA. FDA’s approval of an IND will also require sufficient evidence that the trial will be safe for human subjects.
Cannabis Law Report
OCTOBER 29, 2021
(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. The trial’s secondary endpoints including pharmacokinetics, genotyping, Neuropsychiatric Inventory (NPI), and measurement of suicide severity, have also been completed.
Cannabis Law Report
DECEMBER 6, 2021
“We look forward to Jeff’s significant contributions heading into another year of continued growth and progress for Goldfinch Bio, including a planned interim data readout from TRACTION-2, the ongoing Phase 2 clinical trial of our lead precision kidney medicine candidate, in mid-2022.”.
Expert insights. Personalized for you.
98 
Let's personalize your content